Lorem ipsum dolor sit amet In optio atque rem, quis similique ducimus hic cum eum
Lorem, ipsum dolor sit amet consectetur adipisicing elit. In optio atque rem, quis similique ducimus hic cum eum fugiat beatae dignissimos magni nihil libero blanditiis sapiente sint deleniti at illum!
The diagnosis moment: – the role of POCT HbA1c in undiagnosed diabetes and prediabetes in plowing the progression of diabetes and improving health equ...
Chronic disease management in the post COVID era - the value of point of care testing for cardiovascular risk and kidney disease management in diabete...
Erna Lenters-Westra, and Emma English
Journal of Diabetes Science and Technology 2018;12(4):762-770
Data l'importanza dei test al point-of-care (POCT) nell'assistenza sanitaria, Lents-Westra ed English studiano i criteri di qualità utilizzati per valutare i dispositivi POCT per stabilire se questi funzionano secondo gli stessi standard dei principali analizzatori di laboratorio. Applicano i protocolli EP-5 ed EP-9 del Clinical and ...
Valutazione di quattro dispositivi POC HbA1c usando target di qualità internazionali: Sono adatti per lo scopo?
L'EurA1c Trial Group
Clinical Chemistry 2018;64(8):1183-1192
Lo scopo di questo ampio studio era generare conoscenze e miglioramento dei dosaggi dell'emoglobina glicata (HbA1c) TRAMITE la valutazione delle prestazioni da parte di Paesi e produttori. Sono state valutate le prestazioni analitiche di 2.166 laboratori in 17 Paesi e tra 24 produttori [di questi, 22 erano sistemi di laboratorio e due erano sistemi point-of-care (POC)] se...
EurA1c: Studio "European HbA1c Trial" teso a valutare le prestazioni dei test HbA1c in 2.166 laboratori in 17 Paesi e tra 24 produttori utilizzando il...
Emma English, Larissa-Nele Schaffert and Erna Lenters-Westra
Clinical Laboratory International, November 2018
In questo articolo gli autori discutono i vantaggi dei test al point-of-care (POCT), dall'accelerazione della diagnosi, alla facilità di monitoraggio, all'efficienza in termini di costi e tempi in ambienti rurali e difficili da raggiungere. Proseguono spiegando i diversi metodi analitici per la misurazione dell'HbA1c, i crit...
Test al point-of-care per HbA1c: esigenza clinica e qualità analitica
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Impact of ACR POC testing on the diagnosis and management of diabetic kidney disease
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Should you screen for kidney damage? What do the guidelines say?
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
This webinar will discuss screening for and prevention of chronic disease in severe mental illness (SMI) patients and patients with learning disabilities (LD).
The value of POCT in SMI health checks and patients with learning disabilities for the diagnosis, management and monitoring of diabetes and cardiovasc...
Albuminuria, commonly measured as urine albumin-to-creatinine ratio (ACR), is an under-recognized component of chronic kidney disease (CKD) definition, staging and prognosis.
Albuminuria, elevated serum creatinine and low estimated glomerular filtration rate (eGFR) are key indicators of kidney decline. However, it is unclear if these biomarkers are independent predictors of kidney disease progression in people with type 2 diabetes mellitus (T2DM).
ACR and eGFR as predictors of cardio-renal outcomes in diabetes and kidney disease
Diabetic kidney disease, and chronic kidney disease attributed to diabetes, occurs in 20-40% of patients with diabetes. Acute kidney injury is also one of the most significant complications associated with COVID-19. Point-of-care testing for albumin-creatinine ratio is a valuable tool for monitoring at-risk patients, especially in combination with other comorbid parameters, such as HbA1c and lipids.
ACR point-of-care testing for diabetic kidney disease
The International Diabetes Federation (IDF) published an updated version of its flagship ‘Diabetes Atlas’ in 2019. The atlas covers evidence on the impact of diabetes worldwide, including recommendations for testing and screening.
IDF testing and screening recommendations for diabetes from the 2019 Diabetes Atlas
This clinical practice guideline from the American Heart Association (AHA) aims to give healthcare
providers consistent, clear, and evidence-based guidance for treating patients at risk for atherosclerotic
cardiovascular disease (ASCVD)
AHA cholesterol management guideline for healthcare practitioners
This clinical practice guideline from the American College of cardiology (ACC) and American Heart Association (AHA) provides recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD).
ACC / AHA guideline on the primary prevention of cardiovascular disease
The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.
WHO guidelines on second-and third-line medicines and type of insulin for blood glucose control in diabetes
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease (CKD) represents an update to the 2012 KDIGO guideline.
KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease
Dr. Erna Lenters-Westra, from the Department of Clinical Chemistry, Isala, Zwolle, The Nederlands, talks about HbA1c point-of-care testing, its advantages and perfomance-wise perspective.
HbA1c point-of-care testing: performance and advantages
Join this session to learn from experts in cardiovascular disease prevention about the recent evidence on risk stratification, to get insights from their daily clinical practice and to learn how to use cardiac biomarkers and lipid profile in a more efficient way
Cardiovascular risk assessment and prevention: where do we stand?
In our feature article series, we take a look at publications of particular relevance to point-of-care testing (POCT), providing summaries and expert commentary on the key aspects of the paper and within the wider context of POCT systems.
Point-of-care testing to improve cost-effectiveness of health check programmes in primary care
Cardiovascular diseases are a leading cause of death globally, taking 17.9 million lives each year1. Patients at risk of cardiovascular disease (CVD) may show raised blood pressure, have diabetes or have high lipid levels. The good news is, reducing the risk of cardiovascular disease (such as dyslipidemia, hypercholesterolemia and hypertriglyceridemia) is possible with lipid panel tests to identify risk, and continued testing for monitoring.
A one stop shop: the impact of point-of-care lipid testing on cardiovascular disease screening and management
